Claris Lifesciences Ltd has received an in-principle approval for its anaesthetic drug Propofol in the European Union (EU), enabling the company to process its registration across 25 countries in the Union. Propofol, a flagship product of Claris, is an anaesthetic drug replacing other similar products, as recovery from Propofol is faster.
Europe has one of the most complex procedures for obtaining regulatory approvals. Claris is one of the few companies to have received approval for Propofol in Europe. The market size for Propofol is estimated to be at $750 million worldwide and $150 million in the EU. This registration will benefit Claris as EU is a lucrative market both in terms of revenue and margins.
crackcrack| Company Name | CMP |
|---|---|
| Redington | 227.50 |
| Adani Enterprises | 2228.00 |
| Amrapali Industries | 17.36 |
| Rashi Peripheral | 474.40 |
| PDS | 294.40 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: